Multiple therapeutic compounds can be selectively administered to tumor cells or immune and stromal cells in the TME using SDDSs to combat drug resistance and promote anti-cancer immunotherapy by activating ICD in tumor cells, reversing tumor immunosuppression in the TME, or altering IFN signaling pathways. Here, IFNA1 is linked to neoplasm.